{
  "id": 20406861,
  "title": "Marea Therapeutics at Jefferies Global Healthcare Conference: two shots at crowded markets",
  "url": "https://urgent.news/2026/11/17/marea-therapeutics-at-jefferies-global-healthcare-conference-two",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T08:45:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/marea-therapeutics-at-jefferies-global-healthcare-conference-two-shots-at-crowded-markets-93CH-5032026"
  },
  "original_language": "en",
  "account": "Marea Therapeutics showcased a two-program strategy at the Jefferies Global Healthcare Conference, emphasizing clinical data, human genetics, and a strengthened balance sheet. CEO Josh Lehrer highlighted the company's lead assets with promising early results, though larger studies are required to confirm their profiles. The merger with Lisata Therapeutics and a PIPE financing extend Marea's cash runway through mid-2028. MAR001, targeting severe hypertriglyceridemia, showed triglyceride reductions comparable to ApoC-III inhibitors without a glucose penalty. MAR002, for acromegaly, produced the largest IGF-1 drop in early testing, with no drug-related safety signals. The company aims to capture markets worth $10 billion for severe hypertriglyceridemia and $1.4 billion for acromegaly. Management stated that the next step is to confirm early data in larger patient studies before advancing to phase III trials.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}